Is Nanoviricides struggling financially?

Yes, by its own account. Nanoviricides told the SEC on 15 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Cries for help

Nothing in the filings we have read reads as a plea for help.

Signs of a way out

Grant funding

If successful, we believe this will enable us to apply for Phase II human clinical trials with the US FDA and seek non-dilutive grant funding for the same. We continue to work on further development of NV-387 with the goal of the treatment of pediatric RSV infections.

Form 10-Q, filed 17 Feb 2026. Read it on SEC.gov
Trial result

These clinical and non-clinical findings validate our nanoviricide platform as being capable of clinically relevant development of safe and well tolerated drugs.

Form 10-Q, filed 17 Feb 2026. Read it on SEC.gov

Sector: Biotech/Pharma
Market cap: $33.8M
Source filing: 10-Q 15 May 2026
Balance sheet: 31 Mar 2026

Cash runway

3months

If the burn speeds up

Empty by Jul 2026
6months

If it eases off

Empty by Oct 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$3.2M

Cash burned over the last 12 months

$8.5M

What Nanoviricides told the SEC

…be sufficient to fund the Company’s planned operations and expenditures for at least 12 months from the date of the filing of this Form 10-Q. As a result, substantial doubt exists about the Company’s ability to continue as a going concern. During the nine month period ended March 31, 2026, the Company raised capital of approximately $ 1,909,000 , net of offering expenses, from ATM sales of the Company’s common stock.…

NANOVIRICIDES, INC., Form 10-Q, filed 15 May 2026.

Read the filing on SEC.gov

What this means

Not a bankruptcy filing, and not a prediction.
It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

32.1% share-count increase The company issued stock. Each share now owns 24.3% less of the business than a year ago, before any change in the price.
Cash burn is narrowing It is spending 46% less cash per year than it was, so the runway above is lengthening rather than shortening.

Cash runway

The runway math

What Nanoviricides told the SEC

What this means

What else the numbers show

Other Biotech/Pharma companies that filed the doubt